ArticleeLife2020
Tuberculosis-associated IFN-I induces Siglec-1 on tunneling nanotubes and favors HIV-1 spread in macrophages.
Abstract read
In one paragraph
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Review
- Regulation and function of specialized membrane protrusions in intercellular communication.Nature reviews. Molecular cell biology · 2026Review
- BVDV NS5A Binds to CKAP2 and Activates the PI3K/AKT/mTOR Pathway to Facilitate Virus Transmission Through Tunneling Nanotubes.Veterinary sciences · 2026Article
- Glycolysis inhibition in tuberculosis-driven metabolic rewiring reduces HIV-1 spread in macrophages.Life science alliance · 2026Article
- In silico and in vitro investigations of novel Siglec-1 inhibitors in a microglial cell model.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Tunneling nanotubes induced by pseudorabies virus facilitate viral transmission in neuronal cells to evade the immune system.Cell communication and signaling : CCS · 2026Article
- Type-1 inflammatory imprinting and programmed responsiveness to CD40L enhance Siglec-1-dependent HIV-1 trans-infection by dendritic cells.Frontiers in immunology · 2026Article
- Mycobacterium tuberculosis PE_PGRS62 Protein Inhibits Type I Interferon Responses to Promote HIV-2 Replication by Directly Interacting With Interferon Regulatory Factor 3.The Journal of infectious diseases · 2025Article
- The tuberculosis-associated microenvironment promotes HIV-1 persistence by impairing CD8+ T cell-mediated viral control.bioRxiv : the preprint server for biology · 2025Article
- Beyond the Secretory Pathway: New Insights Into Protein Release.Traffic (Copenhagen, Denmark) · 2025Review
- Targeting interferon responses in juvenile dermatomyositis: Siglec-1 as an in vitro biomarker for JAK inhibitor efficacy.Rheumatology (Oxford, England) · 2025Article
- Protrusion-Derived Extracellular Vesicles (PD-EVs) and Their Diverse Origins: Key Players in Cellular Communication, Cancer Progression, and T Cell Modulation.Biology of the cell · 2025Review
- Alveolar Macrophages in Viral Respiratory Infections: Sentinels and Saboteurs of Lung Defense.International journal of molecular sciences · 2025Review
- Tunneling nanotubes provide a new route for bovine viral diarrhea virus spreading.Frontiers in veterinary science · 2025Article
- Single-cell transcriptomics reveals pathogen interactions and T cell reprogramming in HIV andFrontiers in immunology · 2025Article
- Potential Mechanisms of Tunneling Nanotube Formation and Their Role in Pathology Spread in Alzheimer's Disease and Other Proteinopathies.International journal of molecular sciences · 2024Review
- Cystatin F Depletion inInternational journal of molecular sciences · 2024Article
- The immunosuppressive tuberculosis-associated microenvironment inhibits viral replication and promotes HIV-1 latency in CD4iScience · 2024Article
- Review
- A role for tunneling nanotubes in virus spread.Frontiers in microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Maeva DupontInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.ORCID 0000-0002-0514-4447
Shanti Souriant *Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Luciana Balboa *International associated laboratory (LIA) CNRS 'IM-TB/HIV', Toulouse, France.
Thien-Phong Vu ManhAix Marseille Univ, CNRS, INSERM, CIML, Marseille, France.
Karine PingrisInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Stella RoussetInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Céline CougouleInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Yoann RomboutsInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Renaud PoinclouxInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Myriam Ben NejiInstitut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Carolina AllersTulane National Primate Research Center, Department of Microbiology and Immunology, School of Medicine, Tulane University, Covington, United States.
Deepak KaushalTulane National Primate Research Center, Department of Microbiology and Immunology, School of Medicine, Tulane University, Covington, United States.
Marcelo J KurodaTulane National Primate Research Center, Department of Microbiology and Immunology, School of Medicine, Tulane University, Covington, United States.
Susana BenetIrsiCaixa AIDS Research Institute, Department of Retrovirology, Badalona, Spain.
Javier Martinez-PicadoIrsiCaixa AIDS Research Institute, Department of Retrovirology, Badalona, Spain.
Nuria Izquierdo-UserosIrsiCaixa AIDS Research Institute, Department of Retrovirology, Badalona, Spain.
Maria Del Carmen SasiainInternational associated laboratory (LIA) CNRS 'IM-TB/HIV', Toulouse, France.
Isabelle Maridonneau-Parini *Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
Olivier Neyrolles *Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.ORCID 0000-0003-0047-5885
Christel Vérollet *Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.ORCID 0000-0002-1079-9085
Geanncarlo Lugo-Villarino *Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.ORCID 0000-0003-4620-8491
Funding
Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4MROLE OF INDUCIBLE BRONCHUS ASSOCIATED LYMPHOID TISSUE IN LATENT TUBERCULOSISR01AI111914 · NIAID · WASHINGTON UNIVERSITY · PI KAUSHAL, DEEPAK, KHADER, SHABAANA A. · 2015 to 2025
$11.1MMacrophages in the pathogenesis of AIDSR01AI097059 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KURODA, MARCELO J · 2012 to 2016
$4.0MPerturbation of antigen-specific T cell responses in latent TB/SIV co-infectionR01AI111943 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK, RENGARAJAN, JYOTHI · 2015 to 2019
$3.9MImpact of concurrent HIV and latent TB therapies on Mtb-specific immune function-Diversity SupplementR01AI123047 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK, RENGARAJAN, JYOTHI · 2017 to 2020
$3.9MTargeting HIV Lung Reservoir in the Macaque ModelR33AI110163 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KURODA, MARCELO J · 2016 to 2018
$1.5MTargeting HIV Lung Reservoir in the Macaque ModelR21AI110163 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KURODA, MARCELO J · 2014 to 2015
$457kAgence Nationale de la Recherche ANR-11-EQUIPEX-0003Agence Nationale de la Recherche ANR16-CE13-0005-01Agence Nationale de la Recherche ANRS2014-049Agence Nationale de Recherches sur le Sida et les Hépatites Virales ANRS2014-049Agence Nationale de Recherches sur le Sida et les Hépatites Virales ANRS2018-01Agence Nationale de Recherches sur le Sida et les Hépatites Virales ANRS2020-01ECOS-Sud program A14S01Fondation pour la Recherche Médicale DEQ2016 0334894Fondation pour la Recherche Médicale DEQ20160334902Human Frontier Science Program RGP0035/2016Institute of Health Carlos III CM17/00242National Agency for Science and Technology, Argentina PICT-2015-0055National Agency for Science and Technology, Argentina PICT-2017-1317NIAID NIH HHS R01 AI097059NIAID NIH HHS R01 AI111914NIAID NIH HHS R01 AI111943NIAID NIH HHS R01 AI123047NIAID NIH HHS R21 AI110163NIAID NIH HHS R33 AI110163NIH HHS AI097059NIH HHS AI110163NIH HHS AI111914NIH HHS AI111943NIH HHS OD011104NIH HHS P51 OD011104
Abstract
While tuberculosis (TB) is a risk factor in HIV-1-infected individuals, the mechanisms by which
Indexed as
AnimalsCells, CulturedCoinfectionFemaleGene Expression ProfilingHIV-1HIV InfectionsHumansInterferon Type IMacaca mulattaMacrophages, AlveolarMaleNanotubesSialic Acid Binding Ig-like Lectin 1Tuberculosis, PulmonaryInterferon Type ISialic Acid Binding Ig-like Lectin 1SIGLEC1 protein, humancell biologyco-infectionHIVhumaninfectious diseaseinterferonsmacrophagesmicrobiologymycobacterium tuberculosisrhesus macaquetunneling natotubes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.